专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004106296A3 TRISUBSTITUTED HETEROAROMATIC COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS 审中-公开
标题翻译：作为钙感测受体调节剂的三唑酮异构化合物
公开(公告)号：WO2004106296A3
公开(公告)日：2005-12-22
申请号：PCT/US2004016713
申请日：2004-05-27
申请人： SQUIBB BRISTOL MYERS CO , YANG WU , DICKSON JOHN K , COOPER CHRISTOPHER B , DODD DHARMPAL S , RUAN ZHEMING , SCHNUR DORA M
发明人： YANG WU , DICKSON JOHN K , COOPER CHRISTOPHER B , DODD DHARMPAL S , RUAN ZHEMING , SCHNUR DORA M
IPC分类号： A61K31/4418 , A61K31/444 , A61K31/505 , A61K31/506 , C07D20060101 , C07D213/36 , C07D239/42 , C07D401/04 , C07D403/04 , C07D405/12 , C07D405/14
CPC分类号： C07D239/42 , C07D401/04 , C07D403/04 , C07D405/12 , C07D405/14
摘要： Trisubstituted heteroaromatic compounds having the structure Formula (I) are provided, wherein X is C or N; A and B are each independently CH or N, with the proviso that A and B cannot both be CH; R is Ar-L-; R is hydrogen or alkyl; or R and R can be joined together to form a 4- to 7-membered cycloheteroalkyl ring; R to R , Ar and L are as defined herein. A method for using these compounds to treat diseases associated with abnormal bone or mineral homeostasis is also provided.
摘要翻译：提供具有结构式（I）的三取代杂芳族化合物，其中X是C或N; A和B各自独立地为CH或N，条件是A和B不能都是CH; R 1是Ar-L-; R 2是氢或烷基; 或R 1和R 2可以连接在一起形成4-至7-元环杂烷基环; R 3至R 8中，Ar和L如本文所定义。还提供了使用这些化合物治疗与异常骨或矿物质内稳态相关疾病的方法。

2. 发明申请

WO2006113261A3 INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I 审中-公开
标题翻译： 11-β羟基类固醇脱氢酶I型抑制剂
公开(公告)号：WO2006113261A3
公开(公告)日：2006-11-30
申请号：PCT/US2006013610
申请日：2006-04-12
申请人： SQUIBB BRISTOL MYERS CO , LI JAMES J , HAMANN LAWRENCE G , RUAN ZHEMING , COOPER CHRISTOPHER B , WU SHUNG C , SIMPKINS LIGAYA M , WANG HAIXIA , NAYEEM AKBAR , KRYSTEK STANLEY R JR
发明人： LI JAMES J , HAMANN LAWRENCE G , RUAN ZHEMING , COOPER CHRISTOPHER B , WU SHUNG C , SIMPKINS LIGAYA M , WANG HAIXIA , NAYEEM AKBAR , KRYSTEK STANLEY R JR
IPC分类号： C07D401/12 , A61K31/444 , A61P3/00 , A61P9/00 , A61P25/00 , C07D401/04 , C07D401/14
CPC分类号： C07D213/70 , A61K31/421 , A61K31/426 , A61K31/4439 , A61K31/4965 , A61K31/497 , A61K31/506 , C07D213/71 , C07D213/81 , C07D213/82 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/14 , C07D487/04 , C07D487/08
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein G, L, Q, Z, R 6 , R 7 , and R 8 are defined herein.
摘要翻译：提供了11-β-羟基类固醇脱氢酶I型抑制剂的新型化合物。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病的进展。这些新化合物具有以下结构：（I）或其立体异构体或前药或药学上可接受的盐，其中G，L，Q，Z，R 6，R 7，和本文中定义了R SUB 8。

3. 发明申请

WO2007082264A3 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS 审中-公开
标题翻译：人类胰高血糖素样肽-1调节剂及其在糖尿病治疗中的应用及相关条件
公开(公告)号：WO2007082264A3
公开(公告)日：2007-12-21
申请号：PCT/US2007060383
申请日：2007-01-11
申请人： SQUIBB BRISTOL MYERS CO , HAQUE TASIR SHAMSUL , EWING WILLIAM R , MAPELLI CLAUDIO , LEE VING G , SULSKY RICHARD B , RIEXINGER DOUGLAS JAMES , MARTINEZ ROGELIO L , ZHU YEHENG , RUAN ZHEMING
发明人： HAQUE TASIR SHAMSUL , EWING WILLIAM R , MAPELLI CLAUDIO , LEE VING G , SULSKY RICHARD B , RIEXINGER DOUGLAS JAMES , MARTINEZ ROGELIO L , ZHU YEHENG , RUAN ZHEMING
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/26 , A61K38/28 , C07C271/16 , C07C2603/18 , A61K2300/00
摘要： The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified compounds that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The compounds of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
摘要翻译：本发明提供了具有与天然GLP-1肽类似或更高的生物活性的新型人胰高血糖素样肽-1（GLP-1） - 受体调节剂，因此可用于治疗或预防与GLP活性相关的疾病或病症。此外，本发明提供了新的化学修饰的化合物，其不仅刺激II型糖尿病患者的胰岛素分泌，而且还产生其他有益的促胰岛素应答。这些合成肽GLP-1受体调节剂对蛋白水解切割表现出增加的稳定性，使其成为口服或肠胃外施用的理想治疗候选物。本发明的化合物在糖尿病的功效模型中显示出理想的药代动力学性质和理想的效力。

4. 发明公开

KR20200130362A 항암제로서의 시클릭 디뉴클레오티드 审中-公开
公开(公告)号：KR20200130362A
公开(公告)日：2020-11-18
申请号：KR20207028422
申请日：2019-03-07
申请人： SQUIBB BRISTOL MYERS CO
发明人： FINK BRIAN E , RUAN ZHEMING
IPC分类号： C07H21/02 , A61K31/7105 , A61K39/00 , A61P35/00 , C07K16/28
摘要： 본발명은하기나타낸바와같이화학식 I 및 II의화합물, 뿐만아니라본 발명의화합물을포함하는제약상허용되는조성물, 및다양한장애의치료에서상기조성물을사용하는방법에관한것이다. TIFFpct00189.tif3235 여기서모든치환기는본원에정의되어있다.

5. 发明专利

HRP20220520T1 CIKLIČKI DINUKLEOTIDI KAO AGENSI PROTIV RAKA 未知
公开(公告)号：HRP20220520T1
公开(公告)日：2022-05-27
申请号：HRP20220520
申请日：2019-02-13
申请人： SQUIBB BRISTOL MYERS CO
发明人： FINK BRIAN E , DODD DHARMPAL S , ZHAO YUFEN , QIN LAN-YING , RUAN ZHEMING , HARIKRISHNAN LALGUDI S , KAMAU MUTHONI G , WALKER STEVEN J , CHEN LIBING , PARK PETER KINAM
IPC分类号： C07H21/00 , A61P35/00 , C07H21/02

6. 发明专利

ES2909616T3 Dinucleótidos cíclicos como agentes anticáncer 未知
公开(公告)号：ES2909616T3
公开(公告)日：2022-05-09
申请号：ES19707595
申请日：2019-02-13
申请人： SQUIBB BRISTOL MYERS CO
发明人： FINK BRIAN E , DODD DHARMPAL S , ZHAO YUFEN , QIN LAN-YING , RUAN ZHEMING , HARIKRISHNAN LALGUDI S , KAMAU MUTHONI G , WALKER STEVEN J , CHEN LIBING , PARK PETER KINAM
IPC分类号： C07H21/00 , A61P35/00 , C07H21/02
摘要： Un compuesto de la fórmula (I) **(Ver fórmula)** en la que X es independientemente O o S; X1, X2, X3 y X4 son cada uno independientemente O o NH; R1 y R2 son independientemente **(Ver fórmula)** o **(Ver fórmula)** con la condición de que uno de R1 y R2 debe ser **(Ver fórmula)** Z1 es N o CRa; Z2 es NRb; Ra es H, halógeno, alquilo C1-6 sustituido con 0-6 R5, cicloalquilo C3-6 sustituido con 0-6 R5, CN, NO2, OH, ORa1, SRa1, -C(O)NRa1Ra1, -COORa1, -OC(O)Ra1, -OC(O)NRa1Ra1, -NRa1Ra1, -NRa1 C(O)Ra1, -NRa1COORa1, - NRa1C(O)NRa1Ra1, -NRa1S(O)2Ra1, -NRa1S(O)2NRa1Ra1, -S(O)Ra1, - S(O)NRa1Ra1, -S(O)2Ra1 o S(O)2NRa1Ra1; Rb es H, alquilo C1-6 sustituido con 0-6 R5, cicloalquilo C3-6 sustituido con 0-6 R5, -C(O)Ra1, -C(O)NRa1Ra1, - S(O)2Ra1 o S(O)2NRa1Ra1; Ra1 es H, alquilo C1-3 o cicloalquilo C3-6; R3 es H, CH3, halógeno, -NRa1Ra1 o ORa1; R3a es H, CH3, halógeno, -NRa1Ra1 o ORa1; o R3 y R3a pueden tomarse juntos para formar un carbociclo de 3-4 miembros; o R3 y R3a pueden tomarse juntos para formar un sustituyente C=CH2; R5 es H, halógeno, alquilo C1-3, CN, NO2, OH, ORa1, SRa1, -C(O)NRa1Ra1, -COORa1, -OC(O)Ra1, -OC(O)NRa1Ra1, -NRa1Ra1, -NRa1 C(O)Ra1, -NRa1COORa1, -NRa1C(O)NRa1Ra1, -NRa1S(O)2Ra1, -NRa1S(O)2NRa1Ra1, -S(O)Ra1, - S(O)NRa1Ra1, - S(O)2Ra1 o S(O)2NRa1Ra1; R5a es H o alquilo C1-3; R6 es H, halógeno, alquilo C1-3, CN, NO2, OH, ORa1, SRa1, -C(O)NRa1Ra1, -COORa1, -OC(O)Ra1, -OC(O)NRa1Ra1, -NRa1Ra1, -NRa1 C(O)Ra1, -NRa1COORa1, -NRa1C(O)NRa1Ra1, -NRa1S(O)2Ra1, -NRa1S(O)2NRa1Ra1, -S(O)Ra1, - S(O)NRa1Ra1, - S(O)2Ra1 o S(O)2NRa1Ra1; R8 es H, halógeno, alquilo C1-3, CN, NO2, OH, ORa1, SRa1, -C(O)NRa1Ra1, -COORa1, -OC(O)Ra1, -OC(O)NRa1Ra1, -NRa1Ra1, -NRa1 C(O)Ra1, -NRa1COORa1, -NRa1C(O)NRa1Ra1, -NRa1S(O)2Ra1, -NRa1S(O)2NRa1Ra1, -S(O)Ra1, - S(O)NRa1Ra1, - S(O)2Ra1 o S(O)2NRa1Ra1; R9 es H, halógeno o metilo; Y es CRa o N; m es 0, 1, 2 o 3; o una sal, un tautómero o un estereoisómero de aquel aceptables desde el punto de vista farmacéutico.

7. 发明专利

AR112290A1 DINUCLEÓTIDOS CÍCLICOS COMO AGENTES ANTICÁNCER 未知
公开(公告)号：AR112290A1
公开(公告)日：2019-10-09
申请号：ARP180102134
申请日：2018-07-27
申请人： SQUIBB BRISTOL MYERS CO
发明人： KAMAU MUTHONI G , HARIKRISHNAN LALGUDI S , ZHAO YUFEN , RUAN ZHEMING , QIN LAN , YING - DODD DHARMPAL S , FINK BRIAN E
IPC分类号： C07H19/207 , A61K31/706 , A61K31/7064 , A61K31/7076 , A61K31/78 , A61P35/00 , C07H19/23
摘要： Reivindicación 1: Un compuesto caracterizado por la fórmula (1), en donde X es O ó S; X¹, X², X³ y X⁴ son cada uno, de modo independiente, O ó NH; R¹ y R² son, de modo independiente, restos del grupo de fórmulas (4); Z¹ es N o CRᵃ; Z² es NRᵇ; Rᵃ es H, halógeno, alquilo C₁₋₆ sustituido con 0 - 6 R⁵, cicloalquilo C₃₋₆ sustituido con 0 - 6 R⁵, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; Rᵇ es H, alquilo C₁₋₆ sustituido con 0 - 6 R⁵, cicloalquilo C₃₋₆ sustituido con 0 - 6 R⁵, -C(O)Rᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; Rᵃ¹ es H o alquilo C₁₋₃; R³ es H, CH₃, halógeno, NH₂ u OH; R³ᵃ es H, CH₃, halógeno, NH₂ u OH; o R³ y R³ᵃ se pueden tomar juntos para formar un carbociclo de 3 - 4 miembros; o R³ y R³ᵃ se pueden tomar juntos para formar un sustituyente de C=CH₂; R⁵ es H, halógeno, alquilo C₁₋₃, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; R⁵ᵃ es H o alquilo C₁₋₃; R⁶ es H, halógeno, alquilo C₁₋₃, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NR¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; R⁸ es H, halógeno, alquilo C₁₋₃, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹, C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; R⁹ es H, halógeno o metilo; Y es CR⁵ o N; m es 0, 1, 2 ó 3; n es 0 ó 1; o una de sus sales, tautómeros o estereoisómeros farmacéuticamente aceptables. Reivindicación 20: El compuesto caracterizado por la fórmula (2), en donde X es O ó S; X¹, X², X³ y X⁴ son cada uno, de modo independiente, O ó NH; R¹ y R² son cada uno, de modo independiente, un resto seleccionado del grupo de fórmulas (4); Z¹ es N o CRᵃ; Z² es NRᵇ; Rᵃ es H, halógeno, alquilo C₁₋₆ sustituido con 0 - 6 R⁵, cicloalquilo C₃₋₆ sustituido con 0 - 6 R⁵, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; Rᵇ es H, alquilo C₁₋₆ sustituido con 0 - 6 R⁵, cicloalquilo C₃₋₆ sustituido con 0 - 6 R⁵, -C(O)Rᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; Rᵃ¹ es H o alquilo C₁₋₃; R⁴ es H, CH₃, halógeno, NH₂ u OH; R⁴ᵃ es H, CH₃, halógeno, NH₂ u OH; o R⁴ y R⁴ᵃ se pueden tomar juntos para formar un carbociclo de 3 - 4 miembros; o R⁴ y R⁴ᵃ se pueden tomar juntos para formar un sustituyente de C=CH₂; R⁵ a H, halógeno, alquilo C₁₋₃, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; R⁵ᵃ es H o alquilo C₁₋₃; R⁶ es H, halógeno, alquilo C₁₋₃, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; R⁸ es H, halógeno, alquilo C₁₋₃, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -O(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; R⁹ es H, halógeno o metilo; Y es CR⁵ o N; m es 0, 1, 2 ó 3; n es 0 ó 1; o una de sus sales, tautómeros o estereoisómeros farmacéuticamente aceptables. Reivindicación 68: Un compuesto caracterizado por la fórmula (3), en donde X es O ó S; X¹, X², X³ y X⁴ son cada uno, de modo independiente, O ó NH; R¹ y R² son, de modo independiente, un resto del grupo de fórmulas (5); Z¹ es N o CRᵃ; Z² es NRᵇ; Rᵃ es H, halógeno, alquilo C₁₋₆ sustituido con 0 - 6 R⁵, cicloalquilo C₃₋₆ sustituido con 0 - 6 R⁵, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; Rᵇ es H, alquilo C₁₋₆ sustituido con 0 - 6 R⁵, cicloalquilo C₃₋₆ sustituido con 0 - 6 R⁵, -C(O)Rᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; Rᵃ¹ es H o alquilo C₁₋₃; R⁶ es H, halógeno, alquilo C₁₋₃, OH, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; R⁵ᵃ es H o alquilo C₁₋₃; R⁶ es H, halógeno, alquilo C₁₋₃, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; R⁸ es H, halógeno, alquilo C₁₋₃, CN, NO₂, OH, ORᵃ¹, SRᵃ¹, -C(O)NRᵃ¹Rᵃ¹, -COORᵃ¹, -OC(O)Rᵃ¹, -OC(O)NRᵃ¹Rᵃ¹, -NRᵃ¹Rᵃ¹, -NRᵃ¹C(O)Rᵃ¹, -NRᵃ¹COORᵃ¹, -NRᵃ¹C(O)NRᵃ¹Rᵃ¹, -NRᵃ¹S(O)₂Rᵃ¹, -NRᵃ¹S(O)₂NRᵃ¹Rᵃ¹, -S(O)Rᵃ¹, -S(O)NRᵃ¹Rᵃ¹, -S(O)₂Rᵃ¹ o S(O)₂NRᵃ¹Rᵃ¹; R⁹ es H, halógeno o metilo; Y es CR⁵ o N; m es 0, 1, 2 ó 3; n es 0 ó 1; o una de sus sales, tautómeros o estereoisómeros farmacéuticamente aceptables.

8. 发明专利

CY1111148T1 ΙΜΙΔΑΖΟ- ΚΑΙ ΤΡΙΑΖΟΛΟΠΥΡΙΔΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ 11Β-ΥΔΡΟΞΥΣΤΕΡΟΕΙΔΙΚΗΣ ΑΦΥΔΡΟΓΟΝΑΣΗΣ ΤΥΠΟΥ I 未知
公开(公告)号：CY1111148T1
公开(公告)日：2015-06-11
申请号：CY111100103
申请日：2011-01-31
申请人： SQUIBB BRISTOL MYERS CO
发明人： LI JAMES J , HAMANN LAWRENCE G , WANG HAIXIA , RUAN ZHEMING , COOPER CHRISTOPHER B , LI JUN , ROBL JEFFREY A
IPC分类号： C07D471/04 , A61K31/435 , A61P3/00
摘要： Παρέχονταινέεςενώσειςοιοποίεςείναιαναστολείςτης 11β-υδροξυστεροειδικήςαφυδρογονάσηςτύπου I. Οιαναστολείςτης 11β-υδροξυστεροειδικήςαφυδρογονάσηςτύπου I είναιχρήσιμοιστηναγωγή, πρόληψη, ήεπιβράδυνσητηςεξέλιξηςπαθήσεωνπουαπαιτούνθεραπείαμεαναστολέα 11 β-υδροξυστεροειδικήςαφυδρογονάσηςτύπου I. Οινέεςαυτέςενώσειςέχουντηδομή (I) ήστερεοϊσομερήή φαρμακευτικώςαποδεκτάάλατααυτών, όπουοι W, L, R3, R3a, R3b και R4 ορίζονταιστοκείμενο.

9. 发明专利

SI3752516T1 Ciklični dinukleotidi kot sredstva proti raku 未知
公开(公告)号：SI3752516T1
公开(公告)日：2022-05-31
申请号：SI201930199
申请日：2019-02-13
申请人： SQUIBB BRISTOL MYERS CO
发明人： FINK BRIAN E , DODD DHARMPAL S , ZHAO YUFEN , QIN LAN-YING , RUAN ZHEMING , HARIKRISHNAN LALGUDI S , KAMAU MUTHONI G , WALKER STEVEN J , CHEN LIBING , PARK PETER KINAM
IPC分类号： C07H21/00 , A61P35/00

10. 发明专利

PL3752516T3 DINUKLEOTYDY CYKLICZNE JAKO ŚRODKI PRZECIWNOWOTWOROWE 未知
公开(公告)号：PL3752516T3
公开(公告)日：2022-05-02
申请号：PL19707595
申请日：2019-02-13
申请人： SQUIBB BRISTOL MYERS CO
发明人： FINK BRIAN E , DODD DHARMPAL S , ZHAO YUFEN , QIN LAN-YING , RUAN ZHEMING , HARIKRISHNAN LALGUDI S , KAMAU MUTHONI G , WALKER STEVEN J , CHEN LIBING , PARK PETER KINAM
IPC分类号： C07H21/00 , A61P35/00 , C07H21/02

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式